Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862113 | 0.90 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL29640480 | 0.88 | SIGMAR1 (0.81) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL3075354 | 0.88 | SIGMAR1 (0.81) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL4844753 | 0.87 | SIGMAR1 (0.79) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL6177317 | 0.87 | SIGMAR1 (0.79) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL7268908 | 0.87 | SIGMAR1 (0.79) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL2425554 | 0.86 | SIGMAR1 (0.78) | SIGMAR1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL31462260 | 0.86 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL28741993 | 0.86 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29640479 | 0.86 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367794-B | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-101367794-A | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-02-18 | — | — | CN | disclosed |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | SIGMAR1 480/4885POLB 1635/4885L3MBTL1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.